Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise.The private U.S. company disclosed the equity financing in a Securities and
Are Indian Drug Makers Doing Enough? The Fight Against Fake Medicines Needs More Muscle. Counterfeit and ‘not of standard quality’ drugs are more than a
India’s healthcare future lies in building systems that are proactive in care, powered by technology, and centred around people’s needs, said Lovekesh Phasu, group chief
US President Donald Trump’s recent announcement of 25 percent tariffs on imports from India and US administration letters to drug companies to slash drug prices
The Schemes supporting development and manufacturing of medical devices in the country have helped growth of medical devices exports from the country to almost 88%
US President Donald Trump issued a sharp warning to pharmaceutical giants, calling on them to slash prescription drug prices in the United States or face
The National Pharmacy Commission (NPC) Bill is now awaiting the nod from the Union ministry of health and family welfare. By setting up a centralized
Indian pharma presents an appealing proposition. A strong talent pool, extensive technological and manufacturing competence, regulatory maturity, and a mature chemical industry, stated Sameer Hiremath,
There is an urgent need to eliminate unnecessary animal studies, and establish clear conditions for requiring comparative clinical trials for affordable biosimilars without compromising safety
Glenmark Pharmaceuticals is steering toward a sharper, innovation-driven future over the next four to five years, with a strategic focus on its novel drug portfolio
Copyright © 2025 Gubba Cold Storage Ltd, All rights reserved. Designed, Developed by TenJump